Of 18F MEL050 Using PET/CT in Metastatic Melanoma

Inclusion Criteria: * Written informed consent obtained prior to any protocol-specific procedures * Male and female patients with histologically confirmed melanoma * At least one site of metastatic disease, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care * Age \>/= 18 years * Life expectancy \>/=3 months * ECOG performance score of 0-2 Exclusion Criteria: * Pregnant or breastfeeding females * Systemic anti-melanoma therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F MEL050 PET/CT scan * Patients whose clinical care may be compromised because of the delay resulting from performance of the 18F MEL050 PET/CT scan * Patients whose only metastatic lesion is in the Central Nervous System * Patients with urinary incontinence or patients who cannot comfortably hold their urine for more than 90 minutes * Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study * Patients unwilling or unable to comply with protocol and patients with a history of non compliance or inability to grant informed consent.